+86 189 1304 2753 product@eynoslifescience.com

Anti-human CD66b nanobeads enrich CD66b⁺ granulocytes from human peripheral blood, or deplete them from mixed samples. CD66b (CD67, CGM6, NCA-95) is a 95–100 kD GPI-anchored glycoprotein of the CEA-like subfamily, expressed on granulocytes. In column-based positive selection the CD66b⁺ cells are retained in the column while the remainder flows through; the flow-through is the CD66b-depleted fraction. Purity reaches up to 95% on human peripheral blood.

CatalogueSizeList pricePromo priceManualCOA
PH066BL2 mL, for 1e+9 cells ¥4000¥2400 PDF Search
PH066BM1 mL, for 5e+8 cells ¥2500¥1500 PDF Search
PH066BS0.2 mL, for 1e+8 cells ¥700¥480 PDF Search
Prices are in CNY, ex-works; promo prices apply while the campaign runs. For export orders, ask for a quotation including freight and documents. All products are for research use only (RUO). They are not intended for diagnostic or therapeutic use in humans.

Specifications

ParameterValue
TargetCD66b (CEACAM8); also CD67, CGM6, NCA-95
Molecular weight95–100 kD, GPI-anchored glycoprotein
Antibody formatanti-human CD66b directly conjugated to nanobeads
BufferPBS, 0.1% BSA
Storage4 °C, do not freeze
Recommended doseLysed blood: 20 µL per 1×10⁷ cells; whole blood: 50 µL per mL
Incubation4 °C, 15 min
Purityup to 95% (human peripheral blood)
Manualv26.01

Validation data (human peripheral blood)

Cells were labelled with FITC anti-human CD66b and APC anti-human CD45 before and after separation, at 20 µL beads per 1×10⁷ cells.

SampleBeforeAfter
Lysed peripheral blood (CD66b⁺)55.7%99.3%
Whole blood, no lysis (CD45⁺ / CD66b⁺ within gate)CD45⁺ 15%, CD66b⁺ 88.0%CD45⁺ 93.5%, CD66b⁺ 99.9%

Data are a single experiment from manual v26.01 and were not repeated in-house. No cell counts were provided, so yield and recovery are not reported.

Frequently asked questions

What is CD66b and where is it expressed?

CD66b (also CD67, CGM6, NCA-95) is a 95-100 kD glycosylphosphatidylinositol (GPI)-anchored glycoprotein and a member of the carcinoembryonic antigen (CEA)-like subfamily of the immunoglobulin superfamily. It is expressed on granulocytes and participates in heterophilic adhesion with CD66c. Positive selection therefore yields a granulocyte population dominated by neutrophils.

How does CD66b differ from CD15 and CD16?

The three markers are molecularly distinct. CD66b is a GPI-anchored CEA-family glycoprotein; CD15 (Lewis X) is a fucosylated carbohydrate antigen also enriched on granulocytes; CD16 is Fc gamma receptor III, a transmembrane protein present on both granulocytes and NK cells. CD66b does not depend on Fc receptors, so it is not affected by antibody Fc binding. Validate your own gating combination on your instrument before fixing it.

Can I select from whole blood without lysing red cells?

Yes. The manual gives two protocols. The lysed-blood protocol uses 11 steps at 20 uL beads per 1x10^7 cells with a 15 min incubation at 4 C. The whole-blood protocol uses 6 steps: add 50 uL beads per 1 mL of peripheral blood, incubate 15 min at 4 C and load onto a whole-blood column, with no lysis step.

Which column should I use, M or L?

Choose by total and labelled cell numbers. The M column is rated for fewer than 1x10^7 labelled cells and fewer than 2x10^8 total cells with magnet M1/M8 (500 uL equilibration, 3 x 500 uL wash). The L column is rated for fewer than 1x10^8 labelled cells and fewer than 2x10^9 total cells with magnet L1/L4 (3 mL equilibration, 3 x 3 mL wash). Split the sample across columns above these limits.

Can the beads be used for depletion instead of enrichment?

Yes. CD66b⁺ cells are retained in the column and the flow-through is the CD66b-depleted fraction (steps 8-9 of the manual). Removing residual granulocytes from PBMC or lysed whole blood this way is gentler than repeated red-cell lysis.

Related products

Need a protocol or a quotation?

Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.